Immunovia
Lund
About Immunovia
Immunovia is a diagnostics company specializing in the early detection of pancreatic cancer. Immunovia conducts clinical trials and validation studies to ensure the accuracy and reliability of their tests. The company collaborates with medical institutions and research centers globally to validate its diagnostic tests and bring them to market. By focusing on early detection, Immunovia aims to significantly impact the treatment and management of pancreatic cancer, potentially improving survival rates. The company's innovative approach to using blood-based biomarkers could pave the way for early detection strategies in other cancers and complex diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $54.6M
- Funding stage: IPO
- Last round: Grant (Aug 2024)
- Ticker: nasdaq:IMMNOV
- Website: immunovia.com
- Phone: +46-46-275 60 00
Industries & Categories
Biotechnology, Clinical Trials, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/immunovia-158721 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.